Univercells introduces breakthrough vaccine manufacturing platform

13 Jan 2019

The automated NevoLine bioproduction system that facilitates safer, faster and closed bioprocessing in a much smaller footprint.

Univercells has launched its proprietary NevoLine bioproduction system for vaccines. The system was initially developed as part of a $12 million Grand Challenges grant awarded by the Bill & Melinda Gates Foundation to deliver affordable inactivated polio vaccine (sIPV). Leading the consortium, Univercells was responsible for the NevoLine system, Batavia Biosciences for the polio manufacturing process, and Merck for the purification membrane. After attaining its goals of delivering a very low Cost of Goods for an sIPV below $0.30 per trivalent dose, the consortium has now received a $4 million grant extension to scale-up the manufacturing system and process in preparation for clinical and commercial application. The first NevoLine system will be installed in Batavia Biosciences’ polio dedicated Biosafety level 3 Facility in Leiden, the Netherlands.

Univercells introduces breakthrough vaccine manufacturing platform

Based on a novel process architecture, Univercells designed the automated NevoLine bioproduction system that facilitates safer, faster and closed bioprocessing in a much smaller footprint. Through intensification and chaining of unit steps into a continuous process, users achieve high yields with less time and money invested. The sIPV production process using the NevoLine system is capable of producing trivalent sIPV at less than $0.30/dose, representing a five-fold reduction compared to current manufacturing technologies.

“This challenging 2-year project aimed at delivering a new manufacturing system to drastically decrease cost, footprint and time to market for vaccine manufacturers, and we are pleased to have met these goals,” Hugues Bultot, CEO and co-founder of Univercells said. “The NevoLine system is self-contained into a 6m² series of isolators. A facility designed with four NevoLine units would deliver up to 50 million sIPV doses per year for an estimated capital cost of $20 million. These breakthrough achievements further strengthen our dedication to innovating flexible, scalable and accessible vaccines and biotherapeutics manufacturing solutions.”

Dr Pierre A. Morgon, Non-Executive Director and Advisor to the CEO, added: “Since my first stint in the vaccine industry in 1986, I have seen few technological breakthroughs bringing a genuine opportunity to change the fundamentals of vaccine manufacturing. The technology developed by Univercells heralds a new era in vaccine production. The massive reduction of the upfront capital investment and of the manufacturing footprint required for bulk vaccine and biotherapeutics production will shake the markets to their foundations and enable greater competition by lowering barriers to entry. Public health stands to gain handsomely from these new market dynamics, with biotherapeutics and vaccines being available in large enough volumes and at affordable prices.”

Read More

Related news

Winners of the 16th Pharma Awards

Winners of the 16th Pharma Awards

11 Nov 2019

Companies and individuals from across the whole pharma supply chain recognised for their excellence and commitment.

Read more 
‘FDA should withdraw ANDAs’ says expert

‘FDA should withdraw ANDAs’ says expert

21 Oct 2019

CPhI Worldwide's Annual Report suggests repeat offenders of regulatory infringements should be barred from importing into the US.

Read more 
Sanofi opens its first digitally-enabled, continuous manufacturing facility

Sanofi opens its first digitally-enabled, continuous manufacturing facility

15 Oct 2019

One of the first digital manufacturing facilities in the world to use continuous, intensified biologics production technology.

Read more 
EC approves its first plant-derived cannabis-based medicine

EC approves its first plant-derived cannabis-based medicine

24 Sep 2019

Epidyolex (cannabidiol) approved for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.

Read more 
Integrating glucose sensing and insulin delivery technologies

Integrating glucose sensing and insulin delivery technologies

18 Sep 2019

Collaboration aims to provide a connected device experience for millions of people living with diabetes using insulin.

Read more 
Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

9 Sep 2019

Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.

Read more 
China relaxes import regulations to improve access and availability of affordable medicines

China relaxes import regulations to improve access and availability of affordable medicines

3 Sep 2019

The potential for generics to support the healthcare needs of China is significant.

Read more 
Exciting new vaccine targets killer disease TB

Exciting new vaccine targets killer disease TB

28 Aug 2019

Australian researchers produce early-stage vaccine which is inhaled into the lungs.

Read more 
Switzerland overtakes Germany as Europe’s biggest drug delivery innovator

Switzerland overtakes Germany as Europe’s biggest drug delivery innovator

16 Aug 2019

Pipeline of new drugs has helped drive increased innovation in packaging and drug delivery devices.

Read more 
How real-world data can revolutionise drug development

How real-world data can revolutionise drug development

9 Aug 2019

Utilising the current data environment and its data pools for the benefit of advancing research.

Read more